![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Satisfaction, Tolerability, and Acceptability of Cabotegravir (CAB) + Rilpivirine (RPV) Long-Acting Therapy: LATTE-2 Results
|
|
|
Reported by Jules Levin
Durban IAC 2016 July 18-22
Miranda Murray,1 David Dorey,2 Sandy Griffith,3 Joseph Mrus,4 William Spreen,3 David Margolis3
1ViiV Healthcare, London, UK; 2GlaxoSmithKline, Mississauga, Ontario, Canada; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4Janssen Research & Development, Raritan, NJ, USA
![IAC1](../images/072916/072916-12/IAC1.gif)
![IAC2](../images/072916/072916-12/IAC2.gif)
![IAC3](../images/072916/072916-12/IAC3.gif)
![IAC4](../images/072916/072916-12/IAC4.gif)
![IAC5](../images/072916/072916-12/IAC5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|